Zimeta is a pyrazolone anti-inflammatory drug with a novel mechanism of action. Zimeta is under development for the control of pyrexia (fever) in horses.

Fever is a common condition in nearly three-quarter of a million horses per year and can result in anorexia and lethargy.1 If prolonged, fever may result in debilitating outcomes such as muscle wasting and tissue breakdown.  Recovery can be prolonged with loss of training and delayed competition. There are currently no approved veterinary drugs for the management of fever in horses, therefore practitioners must rely on off-label use of nonsteroidal anti-inflammatory drugs, which has limitations.2,3

Zimeta (dipyrone injection)

The FDA has approved the safety and effectiveness technical sections for dipyrone injection for the control of pyrexia (fever) in horses. On May 16, 2019, KindredBio announced that it had been notified by its contract manufacturer of the active pharmaceutical ingredient (API) dipyrone that the FDA Center for Veterinary Medicine (CVM) had follow up questions, following an inspection in March 2019. Responses have since been submitted to the FDA by the API manufacturer, and the FDA has issued an Establishment Inspection Report indicating that the facility was compliant with good manufacturing practices. KindredBio has reactivated the New Animal Drug Application (NADA). The FDA granted a shortened timeline of 135 days for review of the NADA. Approval is expected in the fourth quarter of 2019 and is dependent on a product- and application-specific facility assessment of the API manufacturer by the CVM review office. Regulatory approval is subject to the typical risks inherent in such a process. Preparations for the commercial launch remain on track.

Dipyrone injection is expected to be the first FDA-approved product for the control of fever in horses. There are eight to nine million horses in the U.S. and currently more than one million are seen by a veterinarian for fever annually. Existing off-label treatments can have serious side effects.

Zimeta (dipyrone oral gel)

The pivotal field effectiveness study for dipyrone oral gel has been completed with positive results. The target animal safety study is also complete, and dipyrone oral gel was found to be well-tolerated. KindredBio has agreed on a path forward with the FDA and bridging studies will likely commence in 2020.

Dipyrone oral gel, which is a proprietary oral gel, is intended as a leave behind for owners to administer to their horse for continued care following dipyrone injection. Accordingly, it is expected to expand use of the drug and build upon the success of dipyrone injection.

1 The Economic Impact of the Horse Industry on the United States, 2005, American Horse Council Foundation (n=18,648 U.S. horse owners/industry suppliers).

2 Epub: Cook VL andBlikslager AT. The use of nonsteroidal anti-inflammatory drugs in critically ill horses.  J Vet Emerg Crit Care (San Antonio). 2015 Jan-Feb; 25(1):76-88.

3 Marshall JF and Blikslager AT.  The effect of nonsteroidal anti-inflammatory drugs on the equine intestine.  Equine Vet J Suppl. 2011 Aug; 39:140-144.